
CLAIMS

That Which Is Claimed Is:

1. A pharmaceutical composition comprising a compound of Formula (I):




(I)

,

or a pharmaceutically acceptable salt thereof, and an osmolyte.

2. The pharmaceutical composition of claim 1, wherein the compound of Formula (I) is of Formula (Ia):




(Ia)

,

or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 1 or 2, wherein the osmolyte is hypertonic saline.

4. A pharmaceutical composition according to claim 3 comprising a compound of Formula (Ia):




(Ia)

,

or a pharmaceutically acceptable salt thereof, and hypertonic saline.

5. The pharmaceutical composition of claim 4, comprising a compound of Formula (Ia):



(Ia)

,

and hypertonic saline.

6. The pharmaceutical composition of claim 3, 4, or 5, wherein the hypertonic saline has a concentration of 4%-5% w/v.

7. The pharmaceutical composition of claim 3, 4, or 5, wherein the hypertonic saline has a concentration of about 4%.

8. The pharmaceutical composition of any one of claims 1-7, further comprising a CFTR modulator.

9. The pharmaceutical composition of any one of claims 1-8, wherein the composition is suitable for inhalation.

10. The pharmaceutical composition of any one of claims 1-8, wherein the composition is a solution for aerosolization and administration by nebulizer.

11. The pharmaceutical composition of any one of claims 1-8, wherein the composition is a solution for administration by metered dose inhaler.

12. The pharmaceutical composition of claim 1 or claim 2, wherein the composition is a dry powder suitable for administration by dry powder inhaler.

13. Use of a pharmaceutical composition according to any one of claims 1-12 in the manufacture of a medicament for promoting hydration of mucosal surfaces and/or improving mucociliary clearance in a human.

14. A pharmaceutical composition according to any one of claims 1-12 for use as a medicament.

15. Use of a pharmaceutical composition according to any one of claims 1-12 in the manufacture of a medicament for treating reversible or irreversible airway obstruction, chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, acute bronchitis, chronic bronchitis, post-viral cough, cystic fibrosis, emphysema, pneumonia, panbronchiolitis, transplant-associate bronchiolitis, or ventilator-associated tracheobronchitis or for preventing ventilator-associated pneumonia in a human in need thereof.

16. Use of a pharmaceutical composition according to any one of claims 1-12 in the manufacture of a medicament for treating dry mouth (xerostomia), dry skin, vaginal dryness, sinusitis, rhinosinusitis, nasal dehydration, dry eye, Sjogren's disease, promoting ocular or corneal hydration, treating distal intestinal obstruction syndrome, otitis media, primary ciliary dyskinesia, esophagitis, constipation, or chronic diverticulitis in a human in need thereof.

17. The use according to claim 15, wherein the medicament is for the treatment of cystic fibrosis.

18. The use according to claim 15, wherein the medicament is for the treatment of chronic obstructive pulmonary disease (COPD).

19. The use according to claim 16, wherein the medicament is for the treatment of primary ciliary dyskinesia.

20. The use according to claim 15, wherein the medicament is for the treatment of bronchiectasis.

21. The use according to any one of claims 13, or 15-20, wherein an effective amount of a pharmaceutical composition of any of claims 1-12 and a CFTR modulator are to be administered.

22. The use according to claim 21, wherein the pharmaceutical composition of any of claims 1-12 and the CFTR modulator are to be administered concomitantly or sequentially in any therapeutically appropriate combination.

23. A kit comprising the pharmaceutical composition of any one of claims 1-12, an aerosolization device selected from a nebulizer, a dry powder inhaler, and a metered dose inhaler, instructions for administering the pharmaceutical composition, and a container.